Option chain shows key data for Aligos Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aligos Therapeutics.

Aligos Therapeutics (NASDAQ:ALGS) Stock, Option Chain

Aligos Therapeutics

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

NYSE

Earnings

Equities

Market Summary

News

Commodities

Economics

Federal Reserve

Markets

Movers

General

$BTC

ALGS

ASAN

BNTX

SPDR Dow Jones Industrial Average ETF Trust

FENC

HSAI

LFMD

NPWR

ORCL

PLTR

RAND

RDFN

SUPV

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks extended last week&#39;s losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Nasdaq, S&amp;P 500 Hit 6-Month Lows As Recession Fears Grow: What&#39;s Driving Markets Monday?

Biotech

Earnings Beats

Penny Stocks

Analyst Ratings

Trading Ideas

ACRV

BEAM

RAPT

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD).

Beam Therapeutics Begins Dosing in Phase I/II AATD Study

Small Cap

Pre-Market Outlook

AULT

CDMO

CLEU

CLIN

GDHG

HPCO

MOMO

SLDB

SNOA

SVFD

THAR

TRKA

XCUR

Shares of  Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter.

Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Aligos Therapeutics Inc

Press Releases

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Aligos Therapeutics to Present at Investor Conferences in December

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Financing

Aligos Therapeutics Announces $105 Million Private Placement Financing

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Aligos Therapeutics Presents Positive Data at APASL 2025

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allakos

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kezar Life Sciences

OSR Holdings

OS Therapies

Passage Bio

Pluri

Q32 Bio

RenovoRx

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

HC Wainwright & Co.

Piper Sandler

Jefferies

SVB Leerink

Comments

Aligos Therapeutics

Aligos Therapeutics (ALGS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga